StemCell Therapy

Researchers from IIT-Madras have developed a clove oil-based emulsion to treat cancer, claiming that the formulation would have enormous scope in the treatment of undifferentiated cancer and can also overcome anti-microbial resistance. The research papers were published recently in the reputed International Journal of Nanomedicine.The researchers, led by professor R Nagarajan, head, department of chemical engineering in IIT Madras, have developed a nano-scale emulsion of clove bud using the spontaneous self-emulsification technique with potent anti-cancer and antibacterial activity. This formulation meets all compliance requirements, they said. According to Nagarajan, while conventional therapies for cancer like radiation, chemotherapy and surgery cause severe damage to normal cells along with other major side-effects, the plant-based essential oils have paved way to devise innovative solutions to these drawbacks of synthetic drugs.The advantages of these emulsions lie in their small droplet size, ease of preparation, optical clarity, good physical stability, improved bio-availability, non-toxicity and non-irritability, said Nagarajan. This formulation would have an enormous scope in the treatment of metastatic cancer. Moreover, the components involved are cost-effective and demonstrate good efficacy, and the technique employed is simple, which is the utmost need for drug development, he said.The team of scientists includes M Joyce Nirmala, post doctoral fellow, Vineet Gopakumar, B Tech student, and Latha Durai, Research Scientistall from IIT-Madras.

Read the original post:
IIT-M develops oil-based cancer therapy - Times of India

Washington D.C: Already known for their shape-shifting abilities, stem cells can now add "death-defying" to their list of remarkable qualities, suggests a novel study.

The new study shows how stem cells, which can contribute to creating many parts of the body, not just one organ or body part, are able to postpone their own death in order to respond to an injury that needs their attention.

The study was done in planarians, which are tiny worms used as model organisms to study regeneration because of their ability to recover from any injury using stem cells.

"Planarian stem cells, even when challenged and under a lot of duress, will still respond to an injury by delaying death," said Divya Shiroor, first author and a graduate student in Dr Carolyn Adler's lab, in the College of Veterinary Medicine.

This could have important implications for cancer research and therapies, particularly when examining chemotherapy and surgery options for patients.

"By understanding how injury prompts planarian stem cells to withstand radiation. We hope to identify genes that, if shared with mammals, could perhaps help hone existing therapies," Shiroor said.

Planarians are commonly used in basic research because of their similarities to humans. Like humans, planarians have stem cells, similar organs and similar genes, but are much more adept at responding to injury, thanks to their higher volume of stem cells and lack of a developed immune system, which in humans complicates the healing process.

"This really simplifies the process of understanding the effects of both injury and radiation on stem cells, and allows us to study it directly without being hampered by parallel processes integral to wound healing, such as inflammation, that get simultaneously triggered in mammals," Shiroor said.

By uncovering the mechanisms that govern stem cells after wounding in a system like planarians, researchers could also apply this knowledge when engineering stem cells to respond similarly in the human body.

Labs have many ways to understand how planarians use stem cells to successfully recover and regenerate, but the Adler lab's combination of radiation and injury to identify a novel stem cell response is unique. The researchers plan on digging deeper to understand how the stressed stem cells know that there is an injury and what role other cells may play in their response.

"We have identified a key gene that is required for stem cell persistence after radiation and injury. and we plan on using this as a stepping stone for further exploration," Shiroor said.

Read more:
Researchers discover stem cells' 'death-defying' quality that aids healing - ETHealthworld.com

Systemic Idiopathic Juvenile Arthritis Treatment Market has recently been added to its extensive repository by Market Research Intellect. This intelligence report includes research based on current scenarios, historical records and future forecasts. In this research report, specific data on various aspects such as type, size, application and end user were checked. It offers a 360-degree overview of the competitive landscape of industries. The SWOT analysis was used to understand the strengths, weaknesses, opportunities and threats faced by companies. This helps companies understand the threats and challenges ahead. The Systemic Idiopathic Juvenile Arthritis Treatment market is growing steadily and the CAGR is expected to improve over the forecast period.

The report includes the latest coverage of the impact of COVID-19 on the Systemic Idiopathic Juvenile Arthritis Treatment industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

**Our FREE SAMPLE COPY of the report gives a brief introduction of the Systemic Idiopathic Juvenile Arthritis Treatment market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

We provide a detailed analysis of key players operating in the Systemic Idiopathic Juvenile Arthritis Treatment Market:

The scope of the Report:

The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Systemic Idiopathic Juvenile Arthritis Treatment market. A competition analysis is imperative in the Systemic Idiopathic Juvenile Arthritis Treatment market and the competition landscape serves this objective. A wide company overview, financials, recent developments, and long and short-term strategies adopted are par for the course. Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in the sales of Systemic Idiopathic Juvenile Arthritis Treatment across the world has been calculated through primary and secondary research. The Systemic Idiopathic Juvenile Arthritis Treatment Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=205377&utm_source=NYH&utm_medium=888

Highlights of the Systemic Idiopathic Juvenile Arthritis Treatment market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Systemic Idiopathic Juvenile Arthritis Treatment market. Additionally, it includes a share of every segment of the Systemic Idiopathic Juvenile Arthritis Treatment market, giving methodical information about types and applications of the market.

Key point summary of the Systemic Idiopathic Juvenile Arthritis Treatment market report:

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It presents an in-depth analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by creating a pin-point analysis of market segments and by having complete insights of the Systemic Idiopathic Juvenile Arthritis Treatment market.

This report helps users in comprehending the key product segments and their future.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Systemic Idiopathic Juvenile Arthritis Treatment market

Chapter 2: Evaluating the leading manufacturers of the global Systemic Idiopathic Juvenile Arthritis Treatment market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Systemic Idiopathic Juvenile Arthritis Treatment market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Finally, the report global Systemic Idiopathic Juvenile Arthritis Treatment market describes Systemic Idiopathic Juvenile Arthritis Treatment industry expansion game plan, the Systemic Idiopathic Juvenile Arthritis Treatment industry knowledge supply, appendix, analysis findings and the conclusion. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Report customization:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=205377&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Systemic Idiopathic Juvenile Arthritis Treatment Market Size, Systemic Idiopathic Juvenile Arthritis Treatment Market Trends, Systemic Idiopathic Juvenile Arthritis Treatment Market Growth, Systemic Idiopathic Juvenile Arthritis Treatment Market Forecast, Systemic Idiopathic Juvenile Arthritis Treatment Market Analysis sarkari result, sarkari exam, sarkari naukri

Our Trending Reports

Big Data Analytics In Healthcare Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Bio-Based Materials Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Bio-Composites Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more here:
Systemic Idiopathic Juvenile Arthritis Treatment Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty

Visit the News Hub

Approach may lead to new treatment approach for osteoarthritis, obesity

Researchers at Washington University School of Medicine in St. Louis found that gene therapy in mice helped build strength and significant muscle mass quickly, while reducing the severity of osteoarthritis. The gene therapy also prevented obesity, even when the mice were fed a high-fat diet.

Exercise and physical therapy often are recommended to help people who have arthritis. Both can strengthen muscle a benefit that also can reduce joint pain. But building muscle mass and strength can take many months and be difficult in the face of joint pain from osteoarthritis, particularly for older people who are overweight. A new study in mice at Washington University School of Medicine in St. Louis, however, suggests gene therapy one day may help those patients.

The research shows that gene therapy helped build significant muscle mass quickly and reduced the severity of osteoarthritis in the mice, even though they didnt exercise more. The therapy also staved off obesity, even when the mice ate an extremely high-fat diet.

The study is published online May 8 in the journal Science Advances.

Obesity is the most common risk factor for osteoarthritis, said senior investigator Farshid Guilak, PhD, the Mildred B. Simon Research Professor of Orthopaedic Surgery and director of research at Shriners Hospitals for Children St. Louis. Being overweight can hinder a persons ability to exercise and benefit fully from physical therapy. Weve identified here a way to use gene therapy to build muscle quickly. It had a profound effect in the mice and kept their weight in check, suggesting a similar approach may be effective against arthritis, particularly in cases of morbid obesity.

With the papers first author, Ruhang Tang, PhD, a senior scientist in Guilaks laboratory, Guilak and his research team gave 8-week-old mice a single injection each of a virus carrying a gene called follistatin. The gene works to block the activity of a protein in muscle that keeps muscle growth in check. This enabled the mice to gain significant muscle mass without exercising more than usual.

Even without additional exercise, and while continuing to eat a high-fat diet, the muscle mass of these super mice more than doubled, and their strength nearly doubled, too. The mice also had less cartilage damage related to osteoarthritis, lower numbers of inflammatory cells and proteins in their joints, fewer metabolic problems, and healthier hearts and blood vessels than littermates that did not receive the gene therapy. The mice also were significantly less sensitive to pain.

One worry was that some of the muscle growth prompted by the gene therapy might turn out to be harmful. The heart, for example, is a muscle, and a condition called cardiac hypertrophy, in which the hearts walls thicken, is not a good thing. But in these mice, heart function actually improved, as did cardiovascular health in general.

Longer-term studies will be needed to determine the safety of this type of gene therapy. But, if safe, the strategy could be particularly beneficial for patients with conditions such as muscular dystrophy that make it difficult to build new muscle.

In the meantime, Guilak, who also co-directs the Washington University Center for Regenerative Medicine and is a professor of biomedical engineering and of developmental biology, said more traditional methods of muscle strengthening, such as lifting weights or physical therapy, remain the first line of treatment for patients with osteoarthritis.

Something like this could take years to develop, but were excited about its prospects for reducing joint damage related to osteoarthritis, as well as possibly being useful in extreme cases of obesity, he said.

Tang R, Harasymowicz NS, Wu CL, Collins KH, Choi YR, Oswald SJ, Guilak F. Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity. Science Advances, published online May 8, 2020.

This work was supported by the Shriners Hospitals for Children, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging and the Office of the Director of the National Institutes of Health (NIH). Grant numbers AR50245, AR48852, AG15768, AR48182, AG 46927, AR073752, OD10707, AR060719, AR057235. Additional funding was provided by the Arthritis Foundation and the Nancy Taylor Foundation for Chronic Diseases.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Go here to read the rest:
Gene therapy in mice builds muscle, reduces fat Washington University School of Medicine in St. Louis - Washington University School of Medicine in...

Rheumatoid Arthritis Drug Market has recently been added to its extensive repository by Market Research Intellect. This intelligence report includes research based on current scenarios, historical records and future forecasts. In this research report, specific data on various aspects such as type, size, application and end user were checked. It offers a 360-degree overview of the competitive landscape of industries. The SWOT analysis was used to understand the strengths, weaknesses, opportunities and threats faced by companies. This helps companies understand the threats and challenges ahead. The Rheumatoid Arthritis Drug market is growing steadily and the CAGR is expected to improve over the forecast period.

The report includes the latest coverage of the impact of COVID-19 on the Rheumatoid Arthritis Drug industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

**Our FREE SAMPLE COPY of the report gives a brief introduction of the Rheumatoid Arthritis Drug market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

We provide a detailed analysis of key players operating in the Rheumatoid Arthritis Drug Market:

The scope of the Report:

The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Rheumatoid Arthritis Drug market. A competition analysis is imperative in the Rheumatoid Arthritis Drug market and the competition landscape serves this objective. A wide company overview, financials, recent developments, and long and short-term strategies adopted are par for the course. Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in the sales of Rheumatoid Arthritis Drug across the world has been calculated through primary and secondary research. The Rheumatoid Arthritis Drug Market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202613&utm_source=NYH&utm_medium=888

Highlights of the Rheumatoid Arthritis Drug market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Rheumatoid Arthritis Drug market. Additionally, it includes a share of every segment of the Rheumatoid Arthritis Drug market, giving methodical information about types and applications of the market.

Key point summary of the Rheumatoid Arthritis Drug market report:

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It presents an in-depth analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by creating a pin-point analysis of market segments and by having complete insights of the Rheumatoid Arthritis Drug market.

This report helps users in comprehending the key product segments and their future.

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Rheumatoid Arthritis Drug market

Chapter 2: Evaluating the leading manufacturers of the global Rheumatoid Arthritis Drug market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Rheumatoid Arthritis Drug market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Finally, the report global Rheumatoid Arthritis Drug market describes Rheumatoid Arthritis Drug industry expansion game plan, the Rheumatoid Arthritis Drug industry knowledge supply, appendix, analysis findings and the conclusion. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Report customization:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=202613&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Rheumatoid Arthritis Drug Market Size, Rheumatoid Arthritis Drug Market Trends, Rheumatoid Arthritis Drug Market Growth, Rheumatoid Arthritis Drug Market Forecast, Rheumatoid Arthritis Drug Market Analysis sarkari result, sarkari exam, sarkari naukri

Our Trending Reports

Carbon Graphite Bushing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Carbonated Bottled Water Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Companion Diagnostic Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Rheumatoid Arthritis Drug Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty

In this report, the global Amniotic Fluid Stem Cell Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Amniotic Fluid Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Amniotic Fluid Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Amniotic Fluid Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

The Amniotic Fluid Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Amniotic Fluid Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23101

Resourceful insights enclosed in the report:

The major players profiled in this Amniotic Fluid Stem Cell Therapy market report include:

key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23101

The market report addresses the following queries related to the Amniotic Fluid Stem Cell Therapy market:

The study objectives of Amniotic Fluid Stem Cell Therapy Market Report are:

To analyze and research the Amniotic Fluid Stem Cell Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Amniotic Fluid Stem Cell Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Amniotic Fluid Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Amniotic Fluid Stem Cell Therapy market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23101

Continue reading here:
COVID-19: Potential impact on Amniotic Fluid Stem Cell Therapy Market Projected to Discern Stable Expansion During 2018 2026 - Cole of Duty

The Global Cell Therapy Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally.

Leading Companies Reviewed in the Report are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Sample Copy of this Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Cell Therapy market Report offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The research report on the global Cell Therapy market includes certain segments by type & application, region and major players. Each type offers data about the production during the slated period of 2015 to 2026. Whereas, the application segment also delivers consumption during the predicted timeframe of 2015-2026. Understanding the segments helps in recognizing the importance of distinct elements that aid the growth of the Cell Therapy market globally. Additionally, it provides in-depth analysis of growth rate and other factors of the global Cell Therapy market in pivotal regions.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

The report provides a thorough assessment of the growth and other aspects of the Cell Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The research report on the world Cell Therapy market has been designed briefly by observing and examining various aspects that discover regional growth of the specific industry. Our analysts team has examined the production cost, revenue data, production, import/export details and key manufacturers of each region. It also evaluates region-wise volume and revenue for the forecast time period between 2020 to 2026. These investigations will help the reader to clearly understand the potential worth of expenditure in a specific region.

For Any Query on the Cell Therapy Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the original post:
Cell Therapy Market 2020 by Various Types, End-Use Application, Major Players, Forecast 2025 - Cole of Duty

This is the latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the report.

A new report titled, Embryonic Stem Cellmarket has been added into its vast repository by Reports Monitor. The report analyzes and estimates the Embryonic Stem Cell market on a global, regional, and country-level. The report offers data of previous years along with in-depth analysis from 2017 to 2022 on the basis of revenue (USD Billion). Besides, the report offers a comprehensive analysis of the factors driving and restraining the growth of the market coupled with the impact they have on the demand over the forecast period. In addition, the report includes the study of lucrative opportunities available in the Embryonic Stem Cell market on a global level.

TheMajorPlayers Covered in this Report:Company A& More.

Get a Sample PDF Report:https://www.reportsmonitor.com/request_sample/906767

The Global XX Market was valued at USD XX Billion in 2020 and is expected to reach USD XX Billion by 2024, expanding at a CAGR of XX% during the forecast period. The scope of the report includes a comprehensive study of global, regional, and local markets for different segments of the market.

In 2018, the global Embryonic Stem Cell market size was million US$ and it is expected to reach a million US$ by the end of 2024, with a CAGR between 2020 and 2024.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Embryonic Stem Cell for each application, including-Medical

Each section of the report reveals critical information about the global Embryonic Stem Cell market that could be used to ensure strong growth in the coming years. Our unique blend of primary and secondary research techniques helped us to recognize hidden business opportunities available in the global Embryonic Stem Cellmarket, besides collecting significant insights of market participants and obtaining precise market data.It includes several research studies such as manufacturing cost analysis, absolute dollar opportunity, pricing analysis, company profiling, production and consumption analysis, and market dynamics.

Regional Analysis For Embryonic Stem Cell Market:

North America(United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

In this study, the years considered to estimate the market size of the Embryonic Stem Cell are as follows:

Grab Your Report at an Impressive Discount! Please click Here@https://www.reportsmonitor.com/check_discount/906767

The study objectives of this report are:

For More Details On this Report:https://www.reportsmonitor.com/report/906767/Embryonic-Stem-Cell-Market

To conclude, the Embryonic Stem Cell Industry report mentions the key geographies, market landscapes alongside the product price, revenue, volume, production, supply, demand, market growth rate, and forecast, etc. This report also provides SWOT analysis, investment feasibility analysis, and investment return analysis.

Contact UsJay MatthewsDirect: +1 513 549-5911 (U.S.)+44 203 318 2846 (U.K.)Email: sales@reportsmonitor.com

Read this article:
Embryonic Stem Cell Market Improvement Status (2020-2024) By Analyzing the Performance of Various Competitors: Company A, and more - NJ MMA News

The Tumor Cell Isolation Kits Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Tumor Cell Isolation Kits market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Tumor Cell Isolation Kits market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28609

The worldwide Tumor Cell Isolation Kits market is an enlarging field for top market players,

Key Players

The key market players operating in the tumor cell isolation kits market are: Thermo Fisher Scientific, Miltenyi Biotec, Cell Biolabs, Inc., STEMCELL Technologies Inc., QIAGEN, Genekam, Menarini Silicon Biosystems, Inc. and others

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28609

This Tumor Cell Isolation Kits report begins with a basic overview of the market. The analysis highlights the opportunity and Tumor Cell Isolation Kits industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Tumor Cell Isolation Kits insight regarding the things which are driving and affecting the earnings of the market. The Tumor Cell Isolation Kits report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28609

Research objectives and Reason to procure this report:-

Finally, the global Tumor Cell Isolation Kits market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Tumor Cell Isolation Kits industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Read more from the original source:
Assessing the Fallout From the Coronavirus Pandemic Tumor Cell Isolation Kits Market Presents an Overall Analysis ,Trends and Forecast 2018 2026 -...

LOS ANGELES, United States:The report on the global Serum-Free Freezing Culture Media industry is just the resource that players need to strengthen their overall growth and establish a strong position in their business. It is a compilation of detailed, accurate research studies that provide in-depth analysis on critical subjects of the global Serum-Free Freezing Culture Media industry such as consumption, revenue, sales, production, trends, opportunities, geographic expansion, competition, segmentation, growth drivers, and challenges.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart):https://www.qyresearch.com/sample-form/form/1669578/global-serum-free-freezing-culture-media-market

The report offers a complete company profiling of leading players competing in the global Serum-Free Freezing Culture Media industry with high focus on share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Serum-Free Freezing Culture Media industry.

Key Players Mentioned in the Global Serum-Free Freezing Culture Media Market Research Report:Thermo Fisher, Merck, Zenoaq, STEMCELL, GE Healthcare, BioLifeSolutions, Bio-Techne, Lonza, Biological Industries, Nippon Genetics, HiMedia, PromoCell

Global Serum-Free Freezing Culture Media Market by Type:With DMSO, DMSO-free

Global Serum-Free Freezing Culture Media Market by Application:Academic & Research Institutes, Pharmaceutical & Biotechnology Companies

In the segmentation section of the report, the authors have elaborately presented key driving factors for different segments of the global Serum-Free Freezing Culture Media industry. The report offers a detailed research study on product type and application segments of the global Serum-Free Freezing Culture Media industry. The segmental analysis provided in the report is expected to help players and investors to identify lucrative growth pockets of the global Serum-Free Freezing Culture Media industry.

As part of geographic analysis of the global Serum-Free Freezing Culture Media industry, the report digs deep into the growth of key regions and countries, including but not limited to North America, the US, Europe, the UK, Germany, France, Asia Pacific, China, and the MEA. All of the geographies are comprehensively studied on the basis of share, consumption, production, future growth potential, CAGR, and many other parameters.

The report answers important questions that companies may have when operating in the global Serum-Free Freezing Culture Media market. Some of the questions are given below:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/1669578/global-serum-free-freezing-culture-media-market

Table Of Content

1 Study Coverage1.1 Serum-Free Freezing Culture Media Product Introduction1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered: Ranking of Global Top Serum-Free Freezing Culture Media Manufacturers by Revenue in 20191.4 Market by Type1.4.1 Global Serum-Free Freezing Culture Media Market Size Growth Rate by Type1.4.2 With DMSO1.4.3 DMSO-free1.5 Market by Application1.5.1 Global Serum-Free Freezing Culture Media Market Size Growth Rate by Application1.5.2 Academic & Research Institutes1.5.3 Pharmaceutical & Biotechnology Companies1.6 Coronavirus Disease 2019 (Covid-19): Serum-Free Freezing Culture Media Industry Impact1.6.1 How the Covid-19 is Affecting the Serum-Free Freezing Culture Media Industry1.6.1.1 Serum-Free Freezing Culture Media Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Serum-Free Freezing Culture Media Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Serum-Free Freezing Culture Media Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered

2 Executive Summary2.1 Global Serum-Free Freezing Culture Media Market Size Estimates and Forecasts2.1.1 Global Serum-Free Freezing Culture Media Revenue Estimates and Forecasts 2015-20262.1.2 Global Serum-Free Freezing Culture Media Production Capacity Estimates and Forecasts 2015-20262.1.3 Global Serum-Free Freezing Culture Media Production Estimates and Forecasts 2015-20262.2 Global Serum-Free Freezing Culture Media Market Size by Producing Regions: 2015 VS 2020 VS 20262.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Global Serum-Free Freezing Culture Media Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.3.3 Global Serum-Free Freezing Culture Media Manufacturers Geographical Distribution2.4 Key Trends for Serum-Free Freezing Culture Media Markets & Products2.5 Primary Interviews with Key Serum-Free Freezing Culture Media Players (Opinion Leaders)

3 Market Size by Manufacturers3.1 Global Top Serum-Free Freezing Culture Media Manufacturers by Production Capacity3.1.1 Global Top Serum-Free Freezing Culture Media Manufacturers by Production Capacity (2015-2020)3.1.2 Global Top Serum-Free Freezing Culture Media Manufacturers by Production (2015-2020)3.1.3 Global Top Serum-Free Freezing Culture Media Manufacturers Market Share by Production3.2 Global Top Serum-Free Freezing Culture Media Manufacturers by Revenue3.2.1 Global Top Serum-Free Freezing Culture Media Manufacturers by Revenue (2015-2020)3.2.2 Global Top Serum-Free Freezing Culture Media Manufacturers Market Share by Revenue (2015-2020)3.2.3 Global Top 10 and Top 5 Companies by Serum-Free Freezing Culture Media Revenue in 20193.3 Global Serum-Free Freezing Culture Media Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Serum-Free Freezing Culture Media Production by Regions4.1 Global Serum-Free Freezing Culture Media Historic Market Facts & Figures by Regions4.1.1 Global Top Serum-Free Freezing Culture Media Regions by Production (2015-2020)4.1.2 Global Top Serum-Free Freezing Culture Media Regions by Revenue (2015-2020)4.2 North America4.2.1 North America Serum-Free Freezing Culture Media Production (2015-2020)4.2.2 North America Serum-Free Freezing Culture Media Revenue (2015-2020)4.2.3 Key Players in North America4.2.4 North America Serum-Free Freezing Culture Media Import & Export (2015-2020)4.3 Europe4.3.1 Europe Serum-Free Freezing Culture Media Production (2015-2020)4.3.2 Europe Serum-Free Freezing Culture Media Revenue (2015-2020)4.3.3 Key Players in Europe4.3.4 Europe Serum-Free Freezing Culture Media Import & Export (2015-2020)4.4 China4.4.1 China Serum-Free Freezing Culture Media Production (2015-2020)4.4.2 China Serum-Free Freezing Culture Media Revenue (2015-2020)4.4.3 Key Players in China4.4.4 China Serum-Free Freezing Culture Media Import & Export (2015-2020)4.5 Japan4.5.1 Japan Serum-Free Freezing Culture Media Production (2015-2020)4.5.2 Japan Serum-Free Freezing Culture Media Revenue (2015-2020)4.5.3 Key Players in Japan4.5.4 Japan Serum-Free Freezing Culture Media Import & Export (2015-2020)

5 Serum-Free Freezing Culture Media Consumption by Region5.1 Global Top Serum-Free Freezing Culture Media Regions by Consumption5.1.1 Global Top Serum-Free Freezing Culture Media Regions by Consumption (2015-2020)5.1.2 Global Top Serum-Free Freezing Culture Media Regions Market Share by Consumption (2015-2020)5.2 North America5.2.1 North America Serum-Free Freezing Culture Media Consumption by Application5.2.2 North America Serum-Free Freezing Culture Media Consumption by Countries5.2.3 U.S.5.2.4 Canada5.3 Europe5.3.1 Europe Serum-Free Freezing Culture Media Consumption by Application5.3.2 Europe Serum-Free Freezing Culture Media Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 U.K.5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Serum-Free Freezing Culture Media Consumption by Application5.4.2 Asia Pacific Serum-Free Freezing Culture Media Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Taiwan5.4.9 Indonesia5.4.10 Thailand5.4.11 Malaysia5.4.12 Philippines5.4.13 Vietnam5.5 Central & South America5.5.1 Central & South America Serum-Free Freezing Culture Media Consumption by Application5.5.2 Central & South America Serum-Free Freezing Culture Media Consumption by Country5.5.3 Mexico5.5.3 Brazil5.5.3 Argentina5.6 Middle East and Africa5.6.1 Middle East and Africa Serum-Free Freezing Culture Media Consumption by Application5.6.2 Middle East and Africa Serum-Free Freezing Culture Media Consumption by Countries5.6.3 Turkey5.6.4 Saudi Arabia5.6.5 U.A.E

6 Market Size by Type (2015-2026)6.1 Global Serum-Free Freezing Culture Media Market Size by Type (2015-2020)6.1.1 Global Serum-Free Freezing Culture Media Production by Type (2015-2020)6.1.2 Global Serum-Free Freezing Culture Media Revenue by Type (2015-2020)6.1.3 Serum-Free Freezing Culture Media Price by Type (2015-2020)6.2 Global Serum-Free Freezing Culture Media Market Forecast by Type (2021-2026)6.2.1 Global Serum-Free Freezing Culture Media Production Forecast by Type (2021-2026)6.2.2 Global Serum-Free Freezing Culture Media Revenue Forecast by Type (2021-2026)6.2.3 Global Serum-Free Freezing Culture Media Price Forecast by Type (2021-2026)6.3 Global Serum-Free Freezing Culture Media Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

7 Market Size by Application (2015-2026)7.2.1 Global Serum-Free Freezing Culture Media Consumption Historic Breakdown by Application (2015-2020)7.2.2 Global Serum-Free Freezing Culture Media Consumption Forecast by Application (2021-2026)

8 Corporate Profiles8.1 Thermo Fisher8.1.1 Thermo Fisher Corporation Information8.1.2 Thermo Fisher Overview and Its Total Revenue8.1.3 Thermo Fisher Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.1.4 Thermo Fisher Product Description8.1.5 Thermo Fisher Recent Development8.2 Merck8.2.1 Merck Corporation Information8.2.2 Merck Overview and Its Total Revenue8.2.3 Merck Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.2.4 Merck Product Description8.2.5 Merck Recent Development8.3 Zenoaq8.3.1 Zenoaq Corporation Information8.3.2 Zenoaq Overview and Its Total Revenue8.3.3 Zenoaq Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.3.4 Zenoaq Product Description8.3.5 Zenoaq Recent Development8.4 STEMCELL8.4.1 STEMCELL Corporation Information8.4.2 STEMCELL Overview and Its Total Revenue8.4.3 STEMCELL Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.4.4 STEMCELL Product Description8.4.5 STEMCELL Recent Development8.5 GE Healthcare8.5.1 GE Healthcare Corporation Information8.5.2 GE Healthcare Overview and Its Total Revenue8.5.3 GE Healthcare Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.5.4 GE Healthcare Product Description8.5.5 GE Healthcare Recent Development8.6 BioLifeSolutions8.6.1 BioLifeSolutions Corporation Information8.6.2 BioLifeSolutions Overview and Its Total Revenue8.6.3 BioLifeSolutions Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.6.4 BioLifeSolutions Product Description8.6.5 BioLifeSolutions Recent Development8.7 Bio-Techne8.7.1 Bio-Techne Corporation Information8.7.2 Bio-Techne Overview and Its Total Revenue8.7.3 Bio-Techne Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.7.4 Bio-Techne Product Description8.7.5 Bio-Techne Recent Development8.8 Lonza8.8.1 Lonza Corporation Information8.8.2 Lonza Overview and Its Total Revenue8.8.3 Lonza Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.8.4 Lonza Product Description8.8.5 Lonza Recent Development8.9 Biological Industries8.9.1 Biological Industries Corporation Information8.9.2 Biological Industries Overview and Its Total Revenue8.9.3 Biological Industries Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.9.4 Biological Industries Product Description8.9.5 Biological Industries Recent Development8.10 Nippon Genetics8.10.1 Nippon Genetics Corporation Information8.10.2 Nippon Genetics Overview and Its Total Revenue8.10.3 Nippon Genetics Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.10.4 Nippon Genetics Product Description8.10.5 Nippon Genetics Recent Development8.11 HiMedia8.11.1 HiMedia Corporation Information8.11.2 HiMedia Overview and Its Total Revenue8.11.3 HiMedia Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.11.4 HiMedia Product Description8.11.5 HiMedia Recent Development8.12 PromoCell8.12.1 PromoCell Corporation Information8.12.2 PromoCell Overview and Its Total Revenue8.12.3 PromoCell Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.12.4 PromoCell Product Description8.12.5 PromoCell Recent Development

9 Production Forecasts by Regions9.1 Global Top Serum-Free Freezing Culture Media Regions Forecast by Revenue (2021-2026)9.2 Global Top Serum-Free Freezing Culture Media Regions Forecast by Production (2021-2026)9.3 Key Serum-Free Freezing Culture Media Production Regions Forecast9.3.1 North America9.3.2 Europe9.3.3 China9.3.4 Japan

10 Serum-Free Freezing Culture Media Consumption Forecast by Region10.1 Global Serum-Free Freezing Culture Media Consumption Forecast by Region (2021-2026)10.2 North America Serum-Free Freezing Culture Media Consumption Forecast by Region (2021-2026)10.3 Europe Serum-Free Freezing Culture Media Consumption Forecast by Region (2021-2026)10.4 Asia Pacific Serum-Free Freezing Culture Media Consumption Forecast by Region (2021-2026)10.5 Latin America Serum-Free Freezing Culture Media Consumption Forecast by Region (2021-2026)10.6 Middle East and Africa Serum-Free Freezing Culture Media Consumption Forecast by Region (2021-2026)11 Value Chain and Sales Channels Analysis11.1 Value Chain Analysis11.2 Sales Channels Analysis11.2.1 Serum-Free Freezing Culture Media Sales Channels11.2.2 Serum-Free Freezing Culture Media Distributors11.3 Serum-Free Freezing Culture Media Customers12 Market Opportunities & Challenges, Risks and Influences Factors Analysis12.1 Market Opportunities and Drivers12.2 Market Challenges12.3 Market Risks/Restraints12.4 Porters Five Forces Analysis13 Key Finding in The Global Serum-Free Freezing Culture Media Study14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.2 Data Source14.2 Author Details14.3 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Visit link:
Serum-Free Freezing Culture Media Market Growth, Projections, Analysis, Trends and Forecast 2026| Thermo Fisher, Merck, Zenoaq, STEMCELL, GE...

France

Masked Parisian statues are helping spread a health message as France is set to enter its last week of strict confinement rules amid a coronavirus crisis.

Along the Trocadero esplanade, across the Seine from the Eiffel Tower, statues were on Sunday wearing masks across their mouths and noses as the city, usually crowded with tourists, stood silent.

Russia

Russia has recorded its highest daily rise in confirmed coronavirus cases with 10,633 new infections, bringing the total to 134,687, with more than half of cases and deaths in Moscow.

But the mortality rate has slowed in recent days and remains much lower, in relative terms, than many other countries.

Russia has said its lower mortality rate was because the Russian outbreak occurred later than in many other countries which gave the authorities more time to prepare.

Russia's nationwide death toll rose to 1280 on Sunday after 58 people died in the last 24 hours, Russia's coronavirus crisis response centre said on its website.

Italy

Deaths from the COVID-19 epidemic in Italy climbed by 174 on Sunday, against 474 the day before, the smallest daily toll of fatalities since March 10.

The daily number of new cases also declined sharply to 1389 from 1900 on Saturday.

In recent weeks of the epidemic that emerged in Italy on February 21, the daily death count has tended to fall on Sundays only to rise again the following day.

Pope Francis on Sunday called for transparent and impartial international scientific cooperation to discover a vaccine for the coronavirus and said it should be made accessible around the world when found.

"It is important to unite scientific capabilities, in a transparent and impartial way to find vaccines and treatments," he said.

Francis said it was also important to "guarantee universal access to essential technologies that allow each infected person, in every part of the world, to receive the necessary medical treatment".

Turkey

The number of people who have died from COVID-19 in Turkey has risen by 61 in the last 24 hours to 3397.

The overall number of cases rose by 1670 to 126,045, the data showed, the highest total outside Western Europe, the United States and Russia.

Spain

Spaniards revelled in a second day of freedom, heading outside in time-slots for age groups on the first weekend adults were allowed out since one of the world's strictest coronavirus lockdowns was imposed in mid-March.

Read the original:
Coronavirus: Latest on COVID-19 from around the world - Monday, May 4 - Newshub

Apoptosis Assay Kit Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Apoptosis Assay Kit market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Apoptosis Assay Kit is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Apoptosis Assay Kit market was valued at USD _ million/billion.

This research report based on Apoptosis Assay Kit market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Apoptosis Assay Kit market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Apoptosis Assay Kit industry.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2657757&source=atm

Apoptosis Assay Kit Market Overview:

The Research projects that the Apoptosis Assay Kit market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

The report on the Apoptosis Assay Kit market provides a birds eye view of the current proceeding within the Apoptosis Assay Kit market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Apoptosis Assay Kit market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Apoptosis Assay Kit market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Leading manufacturers of Apoptosis Assay Kit Market:

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Apoptosis Assay Kit market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of volume for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Apoptosis Assay Kit market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Apoptosis Assay Kit market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Apoptosis Assay Kit market.The following manufacturers are covered in this report:MerckThermo Fisher ScientificBecton DickinsonBio-Rad LaboratoriesPromega CorporationAbcamBio-TechneSartoriusBiotiumCreative BioarrayGeno TechnologyGeneCopoeiaDanaherApoptosis Assay Kit Breakdown Data by TypeFlow CytometryFluorescence MicroscopyOthersApoptosis Assay Kit Breakdown Data by ApplicationDrug Discovery and DevelopmentClinical ResearchStem Cell ResearchBasic Research

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2657757&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2657757&licType=S&source=atm

The Questions Answered by Apoptosis Assay Kit Market Report:

And Many More.

Go here to see the original:
Apoptosis Assay Kit Market to Slip Due to Delays in Production Amidst Coronavirus Outbreak - 3rd Watch News

Peripheral neuropathy is a common complication of primary Sjgren syndrome and may be associated with a diminished health-related quality of life (HR-QoL), according to research results published in Rheumatology International.

Researchers sought to compare HR-QoL outcomes in patients with primary Sjgren syndrome, both with and without peripheral neuropathy. They also aimed to examine the associations between the neurologic complications and components of HR-QoL outcomes using the 36-item Short Form Health Survey (SF-36). Overall, 50 adult patients with primary Sjgren syndrome (median age, 57.5 years; 96% women) were included in the study.

Of the total cohort, 80% (n=40) reported subjective symptoms, including paresthesia or other symptoms that were suggestive of neuropathic pain on a periodic or permanently present basis. In total, 46% (n=23) of patients met the criteria for a diagnosis of peripheral neuropathy (PNS+); the remaining patients were referred to as PNS-.

Researchers indicated the most common peripheral nervous system manifestation to be sensorimotor neuropathy, which was present in 47% of patients who were PNS+. Mononeuropathy was present in 26%, pure axonal sensory neuropathy, axonal motor neuropathy, and small fiber neuropathy were each present in 4.3%, and cranial nerve involvement was present in 17.4% of patients who were PNS+; 1 patient experienced both cranial and sensorimotor neuropathy. Among 35% of patients who were PNS+, neurologic symptoms preceded patients diagnosis of primary Sjgren syndrome.

Investigators studied data from both groups of patients in terms of clinical characteristics and laboratory testing results, and observed similarity in age, disease duration, time from diagnosis, and time of symptom onset. Clinical manifestations, including parotid enlargement, respiratory tract involvement, lymphadenopathy, and hypocomplementemia were significantly more prevalent among patients who were PNS+ vs those who were PNS- (74% vs 44%; 65% vs 37%; 61% vs 19%; and 26% vs 7%, respectively). In addition, patients in the PNS+ vs PNS- group were statistically significantly more likely to frequently use cyclophosphamide because of extraglandular manifestations (17% vs 0%, respectively).

Both groups were also compared based on the results of the visual analog scale (VAS)-pain scale, SF-36, and an interview regarding pain type. Among patients who were PNS+ vs PNS-, median VAS-pain was 3 vs 0, respectively (range, 0-7; P =.229). Neuropathic type pain was often observed across both subgroups but was predominantly among patients who were PNS+ compared with those who were PNS- (70% vs 41%).

Across the 5 domains of the SF-36, patients who were PNS+ vs PNS- had significantly lower results in terms of physical and emotional roles, vitality, bodily pain, and general health (P .05).

Study limitations included potential referral bias in patient selection, researchers inability to conduct neurophysiologic testing in individuals suspected of pure small-fiber neuropathy, and a lack of unambiguous differentiation between Sjgren syndrome-related neuropathy and other forms of neuropathy.

Our study showed that peripheral nervous involvement is frequent in [patients with primary Sjgren syndrome] and it is correlated with worse HR-QoL, the researchers concluded. To get the complete picture of [patients with Sjgren syndrome], a holistic approach starting with a comprehensive assessment of disease activityis needed.

Reference

Jasklska M, Chylinska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjgrens syndrome: A preliminary report [published online March 14, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04543-2

This article originally appeared on Rheumatology Advisor

Originally posted here:
Peripheral Neuropathy Is Common, Associated With Diminished Health-Related Quality of Life in Sjgren Syndrome - Neurology Advisor

Patients with trigeminal nerve damage report moderate-to-severe levels of pain and unpleasantness with evidence for varied site-dependent somatosensory disturbances. This is based on the results of a comprehensive set of psychophysical and electrophysiological investigations published in The Clinical Journal of Pain.

The goal of the current study was to investigate the somatosensory changes related to trigeminal nerve damage using psychophysical and electrophysiological tools.

The study cohort included 37 patients (24 women, mean age 44.6 years) attending Department of Dentistry and Oral Health, Aarhus University, Denmark and Faculty of Odontology, Malm University, Sweden; and Skne University Hospital, Lund, Sweden. Most patients were diagnosed with painful posttraumatic trigeminal neuropathy (n=30), and a minority had nonpainful posttraumatic trigeminal neuropathy (n=7).

Psychophysical tests like quantitative sensory testing and qualitative sensory testing and the electrophysiological nociceptive-specific blink reflex were performed.

The scores from the Pain Catastrophizing Scale (PCS), Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory (STAI) measuring state anxiety (STAI-S) and STAI-T measuring trait anxiety, the 8-item Jaw Function Limitation Scale (JFLS-8), 4-item and 15-item Patient Health Questionnaire (PHQ-4 and PHQ-15), Oral Behaviors Checklist (OBC), and 49-item Oral Health Impact Profile (OHIP-49) were compared between the patients and a group of 20 healthy controls (10 women and 10 men, mean age 37.7 11.4 years).

The main quantitative sensory testing finding observed was an abnormal somatosensory function in 1 parameter in 94.7% of patients with damage to the nerve branches innervating the extraoral region and 88.9% of patients with damage to the nerve branches innervating the intraoral region.

Among 19 patients in whom extraoral QST was performed, at least 1 parameter with loss or gain of somatosensory function was evident in 13 patients (68.4%) on the unaffected side and in 18 patients (94.7%) on the affected side. Among 18 intraorally assessed subjects, in 15 patients (83.3%) there was at least 1 parameter with loss or gain of somatosensory function on the unaffected side and in 16 patients (88.9%) on the affected side.

Qualitative sensory testing identified a side-to-side difference in the tactile and pinprick stimulation in >77% of the patients. An abnormal nociceptive-specific blink reflex response was dependent on the trigeminal branch stimulated; abnormal findings were observed in > 71% of patients for V2 branch and > 42% for the V3 branch stimulation. No correlations were seen between any of the QST and nociceptive-specific blink reflex parameters.

Compared to the healthy participants, patients showed higher scores for pain catastrophizing (10.79.4 vs 17.413.0, P <.001), symptoms of depression (3.23.0 vs 10.29.1, P =.029) and anxiety (STAI-S: 30.17.1 vs 37.913.5; STAI-T: 33.56.2 vs 39.912.7, P =.038), limited jaw function (0.10.5 vs 15.515.5, P <.001), more somatic symptoms, and significantly impaired oral health-related quality of life.

The researchers acknowledged several study limitations, including difficult and low recruitment with potential variation in data collection, use of healthy reference data instead of age- and sex-matched controls, and lack of testing extra-trigeminal sites owing to concern for patient fatigue from multiple investigations.

The present study comprehensively quantifies and profiles the pathophysiological characteristics of trigeminal nerve damage and attests to the need of using clinical history, psychophysical, and electrophysiological investigations for diagnosis of trigeminal nerve damage, concluded the researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Pillai RS, Pigg M, List T, et al. Assessment of somatosensory and psychosocial function of patients with trigeminal nerve damage. Clin J Pain. 2020;36(5):321335. doi:10.1097/AJP.0000000000000806

More here:
Somatosensory and Psychosocial Changes Related to Trigeminal Nerve Damage - Neurology Advisor

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Chemotherapy Induced Peripheral Neuropathy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Chemotherapy Induced Peripheral Neuropathy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Chemotherapy Induced Peripheral Neuropathy market to assist our clients arrive at beneficial business decisions.

The recent published research report sheds light on critical aspects of the global Chemotherapy Induced Peripheral Neuropathy market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Chemotherapy Induced Peripheral Neuropathy market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Chemotherapy Induced Peripheral Neuropathy market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/30209

The recent published study includes information on key segmentation of the global Chemotherapy Induced Peripheral Neuropathy market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Chemotherapy Induced Peripheral Neuropathy market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Chemotherapy Induced Peripheral Neuropathy market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Chemotherapy Induced Peripheral Neuropathy Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/30209

Global Chemotherapy Induced Peripheral Neuropathy Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Chemotherapy Induced Peripheral Neuropathy market. Key companies listed in the report are:

key players and product offerings

Global Chemotherapy Induced Peripheral Neuropathy Market by Geography:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/30209

Some of the Major Highlights of TOC covers in Chemotherapy Induced Peripheral Neuropathy Market Report:

Chapter 1: Methodology & Scope of Chemotherapy Induced Peripheral Neuropathy Market

Chapter 2: Executive Summary of Chemotherapy Induced Peripheral Neuropathy Market

Chapter 3: Chemotherapy Induced Peripheral Neuropathy Industry Insights

Chapter 4: Chemotherapy Induced Peripheral Neuropathy Market, By Region

Chapter 5: Company Profile

And Continue

See more here:
Assessing the Fallout From the Coronavirus Pandemic Chemotherapy Induced Peripheral Neuropathy Market Comprehensive Survey 2019 2029 - Jewish Life...

Dose-limiting toxicities (DLTs) were minimal with the combination of canakinumab plus pembrolizumab (Keytruda), and platinum-based doublet chemotherapy in patients with advanced or metastatic nonsmall cell lung cancer who were treated in the phase II CANOPY-1 study (NCT03631199), demonstrating that the combination could be well-tolerated in these patients.1

Results from the safety run-in portion of the study were presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting. The purpose for part 1 of the CANOPY-1 study was to determine a safe dose of canakinumab for the second portion of the study.

Overall, 30 patients with previously untreated stage IIIB or IIIC or stage IV NSCLC were enrolled to the safety run-in portion of CANOPY-1. For induction therapy, patients in cohort A (n = 10) received canakinumab in combination with pembrolizumab, carboplatin and pemetrexed; cohort B (n = 11) received canakinumab plus pembrolizumab, cisplatin, and pemetrexed; and cohort C (n = 9) received canakinumab plus pembrolizumab, carboplatin, and paclitaxel. All cohorts received maintenance treatment of canakinumab, pembrolizumab, and pemetrexed.

The median age of patients was 63 years (range, 28-77), and the majority of patients were men (73.3%). Patients had an ECOG performance status of 0 (30.0%) or 1 (70.0%) and were either white (60.0%) or Asian (40.0%). Most patients were former smokers (63.3%) while some were never smokers (23.3%) and current smokers (13.3%).

Treatment was discontinued in 6 of the 30 patients (20.0%) and remained ongoing in the remaining 24 patients (80.0%). The reason for treatment discontinuation was progressive disease in 5 patients and death in 1 patient.

No serious adverse events (AEs) were fatal or considered related to canakinumab. AEs led to discontinuation of 1 of the study drugs in 3 patients (10%), all of which were included in cohort C. Hepatitis led to discontinuation of pembrolizumab, and both polyneuropathy and peripheral neuropathy led to discontinuation of chemotherapy.

A dose-limiting toxicity was observed in 1 patient within the first 42 days of therapy, which was grade 3 hepatitis and was deemed related to pembrolizumab in cohort C. The most common grade 3 AEs included pulmonary embolism in 3 patients (2 from cohort A and 1 from cohort C; 10%) and decreased neutrophil count in 2 patients (1 from each cohort; 10%).

Only 1 patient experienced a grade 4 AE, which was cardiac tamponade in cohort B, and 1 patient in cohort B died due to NSCLC.

Based on these findings, the 200-mg dose of canakinumab administered subcutaneously every 3 weeks in combination with the standard dose of pembrolizumab and a platinum-based chemotherapy doublet will be used in the next phase of the CANOPY-1 study, which will be a randomized double-blind, placebo-controlled phase III part to evaluate the safety and efficacy of the triplet regimen. Enrollment for this portion of the study was completed in January 2020 with 643 patients enrolled.

The primary end point of the study was DLTs in the first 42 days of treatment in order to determine the recommended phase III doses of canakinumab in combination with pembrolizumab and a platinum-based doublet chemotherapy. Secondary end points included objective response rate, duration of response, disease control rate, safety, and PK and immunogenicity.

A phase III clinical trial, CANOPY-A (NCT03447769), is underway to evaluate the efficacy and safety adjuvant canakinumab (ACZ885) in patients with nonsmall cell lung cancer (NSCLC) after complete surgical resection versus placebo, according to a presentation at the 2020 American Association for Cancer Research (AACR) Annual Meeting.2

The trial is designed to assess 1500 adult patients with completely resected NSCLC. The rationale for evaluating canakinumab, a monoclonal antibody against pro-inflammatory cytokine IL-1in this patient population is based on previous findings from the phase III CANTOS study, which evaluated the role of this agent in preventing cardiovascular events among patients with myocardial infarction who had an elevated C-reactive protein (CRP) level.

The clinical development of canakinumab as an antineoplastic agent is somewhat atypical as a particularly compelling piece of evidence supporting the potential clinical efficacy of canakinumab in NSCLC comes from a clinical study of an unrelated disease, said Edward B. Garon, MD, MS, director, Thoracic Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, during his presentation at the 2020 AACR Annual Meeting.

Results from the CANTOS study, which were published in the New England Journal of Medicine in 2017, prompted interest in the agents potential as therapy in lung cancer. The trial demonstrated a highly significant reduction in lung cancer incidence, as well as mortality, in the group of patients that received canakinumab compared with placebo.3

As part of that cardiovascular study, which evaluated over 10,000 patients, the incidence and mortality from lung cancer was reduced among patients receiving canakinumab, Garon said.2 Intriguingly, this effect was dose-dependent with the greatest reduction occurring among patients treated at the highest dose level evaluated.

IL-1 is an inflammatory cytokine released by various cell types to promote tumor growth, progression, and metastasis. It upregulates tumor-association inflammation, which is known to suppress antitumor immune responses. Canakinumab targets tumor-promoting inflammation to reduce immunosuppression by binding to human IL-1 and neutralizing the activity by blocking its interaction with IL-1 receptors.2

The multicenter randomized double-blind, placebo-controlled CANOPY-A study is enrolling patients with stage IIA-IIIA and IIIB NSCLC and an ECOG performance status of 0 or 1. Patients can have any histology and must have recovered from all toxicities related to prior systemic therapy to grade 1, although patients with any grade alopecia and grade 2 or less neuropathy are allowed to enter the study as well.

If patients have unresectable or metastatic disease, they are ineligible to participate. They will also be unable to enter the study if they received neoadjuvant chemotherapy or neoadjuvant radiotherapy. If there is a presence or a history of a malignant disease besides the resected NSCLC that has been diagnosed or required therapy within the past 3 years, they could not enter the study. Patients with a history of current diagnosis of cardiac disease or uncontrolled diabetes are also ineligible.

Patients enrolled to the CANOPY-A study will undergo appropriate adjuvant therapy, which is primarily inclusive of cisplatin-based chemotherapy and in some cases radiotherapy if indicated by local guidelines or practices. Patients are randomized 1:1 to receive 18 cycles of either Canakinumab at 200 mg or placebo subcutaneously every 3 weeks.

The primary end point of the trial is disease-free survival. Secondary end points include overall survival, lung cancer-specific survival, adverse events, and EKG and laboratory abnormalities. Additional secondary end points also include PK evaluation, anticanakinumab antibodies, and health-related quality of life.

A biomarker substudy will also be conducted under CANOPY-A to determine the impact of surgical resection on biomarkers, such as CRP and cytokines. Eligibility criteria for this substudy mirror the criteria for the randomized study post-resection. Patients will undergo blood sample collection both pre- and post-surgery.

Canakinumab has already been approved by the FDA for the treatment of a spectrum of autoinflammatory conditions, such as rheumatologic disorders.3

References

See the original post here:
Canakinumab Plus Pembrolizumab and Chemotherapy Appears Safe in Advanced NSCLC - Targeted Oncology

LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

Some aspects of the science and art of practicing veterinary medicine are constant, whereas other parts change rapidly. Not surprisingly, information is key to success, and in todays world, this issue is not really the ability to access information. What is needed is the ability to timely identify relevant information and distinguish useful pieces from the growing noise of information overload.

For theTexas Tech University School of Veterinary Medicine in Amarillo, the opportunity to address this need by building a focused information system from the ground up is a unique opportunity. Each course and lecture possess its own unique requirement for instructional and informational resources, from textbooks and clinical studies to data sets, recorded laboratory sessions and expert videos.

Some of those courses may require students to access information remotely or in the field. Content to help students develop the skills to rapidly access and distinguish information has been weaved throughout the curriculum.

Finding someone who can bring that all together for the School of Veterinary Medicine has been a focus with the first class planned to start in just over a year. Also important for the school is someone who will take shared ownership of its mission of serving the needs of rural and regional communities, provide access to affordable education, and foster its core values.

Howard Rodriguez-Mori is that person.

Rodriguez-Mori joins the faculty of the new Texas Tech School of Veterinary Medicine in Amarillo as an associate professor of Library and Information Services. He began his duties on May 1.

It is exciting to join the School of Veterinary Medicine at Texas Tech and to be part of the team that will develop the program, Rodriguez-Mori said. This is a once-in-a-lifetime opportunity, and that is why I am so excited about the role I will play at the School of Veterinary Medicine. I genuinely believe it is essential for our clinical students to feel and know that the school is backing them up regardless of their clinical practice locations, and I take to heart making sure they get the support they need.

Rodriguez-Mori arrives at Texas Tech after serving dual roles in the Florida State University System. He served as the Open Educational Resources Coordinator and Associate Librarian at Florida International University and as an assistant professor of Library and Information Studies at Florida State University.

His library education includes courses in medical librarianship, evidence-based practice and multicultural communication and service. The past two years, he has conducted research into the roles and influence of libraries, government agencies and religious and non-profit influence on Hurricane Maria survivors taking refuge in Central Florida. This has led to a comprehensive systematic review of hurricane-related post-traumatic stress syndrome research.

Information overload is something we all talk about, saidGuy Loneragan, dean of the School of Veterinary Medicine. Weeding through the never-ending onslaught to quickly and accurately target information we can use to make a difference for our clients and their animals is a critical skill we need to and can develop in our students. Dr. Mori is the right person to do that. He will make an impact in the lives of our students and also for our faculty and staff. Our school is so much better for Dr. Mori being part of it.

Rodriguez-Mori earned both his masters degree in Library and Information Science (2001) and doctorate in Information Use Studies (2009) from Florida State, and in 2019 he completed a masters degree in Marketing and Management Communication.

He has been awarded the SABIO Post-Graduate Diversity Residency Program from the University of Arizona, the Diversity Faculty Fellowship from the University of Denver and the Project Athena Doctoral Fellowship from Florida State University.

Dr. Rodriguez-Mori will be creating the resources our faculty, staff and students need to be successful in using and navigating the all-encompassing area of informational services, saidJohn Dascanio, senior associate dean for academic and student affairs. This is a crucial position for the school to ensure the connectivity of our participants to the information they may need to make informed decisions in many areas, including animal health, research and education. He will have a long and lasting impact on our program.

Rodriguez-Mori joins Loneragan, Dascanio, associate dean for clinical programsBritt Conklin, professor of surgeryDavid Dutton, assistant professor of general veterinary practiceBethany Schilling, professor of medicineLszl Hunyadi, professor of surgeryNancy Zimmermanand visiting professorJerry Blackon the faculty for the School of Veterinary Medicine. Additional faculty members will be added over the remainder of the spring, then over the summer and fall.

About the School of Veterinary MedicineThanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo, established in 2018, is working to enroll its first class in the fall of 2021, pending approval by the American Veterinary Medical Association (AVMA) Council on Education.

The School of Veterinary Medicine will recruit and select students with a passion to practice and succeed in rural and regional communities. Its curriculum is focused on the competencies and skills necessary for success in practices that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

In June,Gov. Greg Abbott signed into law the biennial state budget, which appropriated $17.35 million for the School of Veterinary Medicine in Amarillothat will go toward operational needs in order to get the school up and running. The appropriation included language directing Texas Tech to move forward in establishing the school.

(News release from Texas Tech University)

Read more from the original source:
Veteran library and information sciences expert to lead TTU School of Veterinary Medicines library services - KLBK | KAMC | EverythingLubbock.com

The way our pets receive veterinary care changed dramatically two months ago.

One day we were in the exam room with them. The next, we were driving to the clinic when we had an appointment, calling from our cars to announce our arrival, and staying in our cars while masked vet techs came and took pets inside for exams.

Telehealth is likely to be with us for a while.

High-tech accommodations that veterinarians and pet owners have made to deal with COVID-19 will likely remain in the future. Phone calls, video and social media may all play a role in the way pets receive care and the way we witness it.

For instance, if you cant go in with your pet, can you still see the exam and communicate with the veterinarian?

Absolutely, says Dr. Peter Weinstein, executive director of the Southern California Veterinary Medical Association. Once the pet is in the exam room, he says, its easy to initiate a Zoom, Skype or FaceTime call with the client so they can see whats going on.

Dr. Julie Reck foresees utilizing video and social media more frequently to let owners see whats going on if a pet has to go to the back for a procedure or is recovering from surgery.

We do a lot on our social media for our veterinary page, she says. We get video content of our patients all the time, whether thats while were in the exam room or if theyre in the back treatment area. If were going to change that dynamic and separate the pet parent and the pet, we need to up the ante with that a little bit.

Anxious about letting your pet go into the veterinary clinic without you? Its not surprising that your pet might be weirded out by the masked, gloved and gowned technician and veterinarian.

And separating pets and their people isnt ideal, but veterinary staff members are easing pet anxiety by using low-stress handling techniques, food rewards, stress relievers such as pheromone diffusers or soft music, and nonskid surfaces on exam tables to help them remain calm and comfortable.

In the not so distant future, remote health care may become more common for what were once routine in-clinic visits. Beyond a pandemic situation, it can benefit people who are sick or who dont have access to transportation. Its useful in remote areas where specialist care isnt available and in cases where pets simply cant tolerate a visit to the vet.

Maybe your dog has a lump on his chin. You could take a photo of the lump and e-mail or text it to your veterinarian for advice on whether it can wait or if your pet needs to be treated immediately.

Whenever the pandemic is over, lingering fear will likely affect the way veterinary medicine is delivered. We may see hybrid models combining traditional delivery of veterinary medicine with new drive-up, drop-off or telehealth services.

Weinstein counsels patience to pet owners and veterinarians who are navigating new territory and are concerned about their health as well as that of their families and pets.

If we can all respect one anothers needs, well all come out of this just fine, he says.

Read the original:
Texting your vet? The future of pet care could be virtual visits - Minneapolis Star Tribune

Travis Sulfridge, DVM is a 2011 graduate of Whitley County High School. After earning an undergraduate degree from the University of the Cumberlands he went on to Auburn University in Alabama, where he graduated in May of 2019 from the College of Veterinary Medicine.

In the past year, he has practiced at the Williamsburg Veterinary Clinic alongside Dr. Michael Culver. Sulfridge is a general practitioner, treating both large and small animals, and in addition to the work he does in the clinic, he will also make farm calls when possible.

I grew up on a small cattle farm, Sulfridge said. I have always loved animals, and I wanted to do something that would allow me to give back to my community while also working with animals at the same time.

Sulfridge said that he has been happy to be working in his hometown this past year, free of the stress that goes along with being in school full time, and able to spend more time with his wife and young daughter. As for how things have been since the COVID-19 pandemic earlier this year, he explained, We were seeing emergency-only cases for a period of time, and everything has been curbside service. Our clients have been great, though, and most have been really understanding as we try to keep up with all of the social distancing guidelines. We have been opening back up some of our other services lately, doing vaccinations and surgeries again now.

Sulfridge said the phones have been ringing off the hook since restrictions have been lifted on some of the services that had to be suspended recently.

As for now, we are still taking it slow, Sulfridge said. Everything will still be curbside, but we will try to increase the amount of patients that we see. We want to be able to see everyone that we absolutely can.

Pet owners have been curious about how COVID-19 could affect their four-legged friends since the beginning of this pandemic, but there have been conflicting reports about it, depending on who you listen to. When asked to clarify, Sulfridge said, So far, there have been two cases of cats with COVID, both in New York. To-date there have been no transmissions of the disease from pets to humans, but there is still a chance of a pet catching it from their owner.

When asked how to reduce the risk of this happening, Sulfridge said, For now, dont kiss them and dont share any kind of utensils. Try to keep them away from people or other pets that live outside of the house. The American Veterinary Medical Association (AVMA) has plenty more good information on the topic at http://www.avma.org.

For more on the Williamburg Veterinary Clinic, look them up on Facebook or call 606-549-5444.

Read more:
W'burg vet Travis Sulfridge talks COVID-19 and its potential effects on pets, pet owners The News Journal - The News Journal

Dr. Robin Downing

Pain expert Robin Downing, equine practitioner Harry Werner and Michigan State University Professor Janice Siegford are the recipients of American Veterinary Medical Association awards.

The honors, announced May 6, are as follows:

A graduate of the University of Illinois College of Veterinary Medicine, Dr. Downing was recognized for her work in protecting and promoting the human-animal bond.

She is the owner and medical director at both the Downing Center for Animal Pain Management and the Windsor Veterinary Clinic in Windsor, Colorado. She holds a masters degree in bioethics, is a diplomate of the American Academy of Pain Management and the American College of Veterinary Sports Medicine and Rehabilitation, and is a certified veterinary pain practitioner and a certified canine rehabilitation practitioner.

Dr. Downing has devoted her career to improving the health of animals and strengthening and prolonging the bond between people and animals, said AVMA President John Howe, DVM. Bestowing her with this award is a fitting tribute to Dr. Bustad, an outstanding educator, scientist, humanitarian and pioneer in the field of human-animal interactions.

The late Dr. Bustad was a Delta Society president and a dean at the Washington State University College of Veterinary Medicine.

Elected to the International Equine Veterinarians Hall of Fame in 2013, Dr. Werner is the longtime owner of an equine practice in North Granby, Connecticut.

A graduate of the University of Pennsylvania School of Veterinary Medicine, he represented the American Association of Equine Practitioners on the AVMAs Animal Welfare Committee and represented the AVMA and AAEP on the Unwanted Horse Coalition. He received the AAEPs

Distinguished Life Member Award in 2017.

Dr. Werners dedication, excellent communication skills, and the innate ability to maneuver around and through emotional and oftentimes misunderstood welfare conditions are his greatest strength, said Tom Lenz, DVM, MS, DACT, the recipient of the 2010 Animal Welfare Award. But it is his passion and sincere belief in the well-being of all animals that truly drove him to be the success that he is.

Dr. Siegford, a professor of animal science and welfare, helped development the AVMA Animal Welfare Assessment Contest and has served on its coordinating committee since 2007.

The Humane Award is given annually to a non-veterinarian who advances the welfare of animals through leadership, public service, education, advocacy, or research or product development.

Dr. Siegford has been a champion of animal welfare for many years and has done so much to integrate animal welfare into veterinary education, Dr. Howe said.

The three awards are handed out annually. The 2019 winners were Karen Vernau, DVM, MS, DACVIM (Bustad Companion Animal Veterinarian of the Year), Joanne Paul-Murphy, DVM, Ph.D., DACZM (Animal Welfare Award) and Sonia Hernandez (Humane Award).

Did you know a subscription to Todays Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Todays Veterinary Business weekly e-newsletter.

Link:
AVMA honors 2 veterinarians and professor - Today's Veterinary Business Magazine